Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2012

Global Markets Direct
March 19, 2012
210 Pages - SKU: GMD3811121
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2012', provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections.
  • A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Drug Discovery reports by Global Markets Direct

Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2014 by Global Markets Direct
Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2014’, provides an overview of the ...
Neuroblastoma - Pipeline Review, H2 2014 by Global Markets Direct
Neuroblastoma - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Neuroblastoma - Pipeline Review, H2 2014’, provides an overview of the Neuroblastoma’s therapeutic pipeline.This report provides comprehensive ...
Myelodysplastic Syndrome - Pipeline Review, H2 2014 by Global Markets Direct
Myelodysplastic Syndrome - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Myelodysplastic Syndrome - Pipeline Review, H2 2014’, provides an overview of the Myelodysplastic Syndrome’s therapeutic pipeline.This ...
Small-Cell Lung Cancer - Pipeline Review, H2 2014 by Global Markets Direct
Small-Cell Lung Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Small-Cell Lung Cancer - Pipeline Review, H2 2014’, provides an overview of the Small-Cell Lung ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 500  
    Global Site License  USD 1,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!